Saturday 17 October 2026
Export QSI’s income statement to Excel — free account
Quantum-Si Incorporated
QSI Healthcare Medical Devices
Quantum-Si Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, down 20.3% from fiscal 2024. In the quarter to June 2026, revenue fell 41.8%, EPS grew 31.3% and free cash flow grew 9.75%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.12
0.19
−14.50%
Follow QSI
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | — | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — |
P/S ratio |
89.30 | 126.43 | 265.10 | — | — | — | — | — |
Altman Z-Score |
0.36 | 3.31 | 3.87 | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
0.75 | 1.47 | 8.39 | — | — | — | — | — |
Beneish M-Score |
2.00 | (1.07) | — | — | — | — | — | — |
P/Operating CF |
(13.31) | (16.90) | (13.68) | — | — | — | — | — |
P/B ratio |
0.99 | 1.79 | 1.06 | — | — | — | — | — |
Price to Tangible BV |
0.99 | 1.80 | 1.06 | — | — | — | — | — |
EV/Sales |
22.43 | 57.89 | 26.90 | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | — | — | — | — |
EV/Operating CF |
(0.58) | (2.02) | (0.31) | — | — | — | — | — |
EV/FCF |
(0.56) | (1.92) | (0.29) | — | — | — | — | — |
Quick Ratio |
7.30 | 11.60 | 22.23 | 22.38 | 40.96 | 13.60 | — | — |
Current Ratio |
7.64 | 11.99 | 22.94 | 22.81 | 41.39 | 13.75 | — | — |
Net Debt/EBITDA |
1.36 | 1.87 | 2.41 | 3.14 | 4.92 | 0.98 | 0.00 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 4.31% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 | — |
Asset Turnover |
0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.93 | 0.87 | 0.98 | 0.68 | 0.70 | 0.89 | 0.86 | — |
Capex/Depreciation |
0.71 | 1.22 | (1.27) | (0.89) | (5.54) | (0.52) | (1.59) | — |
Interest Coverage |
— | — | — | — | (19,381.60) | (4,076.78) | — | — |
| (46.52%) | (41.48%) | (30.45%) | (31.69%) | (59.87%) | (23.08%) | 0.00% | — | |
| (41.07%) | (36.99%) | (27.83%) | (29.61%) | (34.93%) | (180.40%) | 0.00% | — | |
ROIC |
(126.60%) | (1,166.58%) | (500.48%) | (1,046.38%) | (1,057.02%) | 0.00% | 0.00% | — |
Return on Tangible Assets |
(61.04%) | (46.80%) | (35.41%) | (36.86%) | (20.02%) | (98.69%) | 0.00% | — |
Average Days of Receivables |
779.00 | 159.11 | 124.14 | 0.00 | 0.00 | 0.00 | — | — |
Research and Development Expense of Revenue |
2,206.86% | 1,950.33% | 6,194.55% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
1,837.19% | 1,652.55% | 4,125.14% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
442.24% | 290.61% | 787.06% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Graham Net Nets |
0.69 | 0.48 | 0.84 | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | — | — | — | — | — |
Earnings Yield |
(47.27%) | (26.30%) | (33.50%) | — | — | — | — | — |
Free Cash Flow Yield |
(44.70%) | (23.91%) | (34.62%) | — | — | — | — | — |
Revenue per Share |
0.01 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.48) | (0.61) | (0.67) | (0.65) | (0.84) | (6.08) | (5.97) | — |
Capex per Share |
(0.01) | (0.03) | (0.04) | (0.08) | (0.07) | (0.09) | (0.24) | — |
Free Cash Flow per Share |
(0.49) | (0.65) | (0.70) | (0.73) | (0.91) | (6.17) | (6.21) | — |
Cash per Share |
0.82 | 1.46 | 1.82 | 2.52 | 5.92 | 6.89 | 0.00 | — |
Shareholders Equity per Share |
1.11 | 1.50 | 1.92 | 2.58 | 5.99 | (29.82) | 0.00 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
1.11 | 1.50 | 1.92 | 2.58 | 5.99 | (29.82) | 0.00 | — |
Free Cash Flow |
(97.23) | (92.44) | (99.31) | (101.30) | (72.58) | (33.03) | (31.95) | — |
Working Capital |
152.84 | 199.82 | 254.70 | 342.48 | 465.64 | 35.10 | — | — |
Capital Expenditures |
(2.52) | (4.64) | (5.27) | (10.74) | (5.76) | (0.46) | (1.24) | — |
Net Current Asset Value |
150.48 | 185.56 | 239.68 | 325.40 | 450.98 | (162.46) | 0.00 | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | — | — | — | — |
Capex to Sales |
1.03 | 1.52 | 4.87 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
(0.27) | (0.24) | 0.26 | 0.72 | 0.12 | 0.45 | 0.00 | — |
Cash ROIC |
(25.38%) | (21.75%) | (18.76%) | (14.27%) | (7.65%) | 27.29% | 0.00% | — |
Accounts Receivable Turnover |
0.75 | 3.60 | 3.77 | 0.00 | 0.00 | 0.00 | — | — |
Accounts Payable Turnover |
0.72 | 0.79 | 0.21 | 0.71 | 0.44 | 0.38 | — | — |
Inventory Turnover |
0.35 | 0.36 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
461.73 | 483.41 | 1,085.17 | 551.31 | 1,189.67 | 542.60 | — | — |
Days of Inventory on Hand |
909.51 | 1,018.14 | 2,424.12 | 0.00 | 0.00 | 0.00 | — | — |
Average Receivables |
3.27 | 0.85 | 0.29 | 0.54 | 0.71 | 0.71 | — | — |
Average Payables |
1.78 | 1.85 | 2.83 | 3.65 | 2.36 | 2.36 | — | — |
Average Inventory |
3.63 | 4.01 | — | — | — | — | — | — |
Average Assets |
246.74 | 273.06 | 344.87 | 447.36 | 271.91 | 20.30 | 0.00 | — |
Average Common Equity |
217.82 | 243.52 | 315.16 | 417.87 | 158.65 | 158.65 | — | — |
Columns are period end dates